Disease Model
Espacenet
Family 88517590
Abstract
[0001] The present invention provides a method for producing an arrhythmia disease model. lt also provides a corresponding arrhythmia disease model or arrhythmia disease model system. The arrhythmia disease model or arrhythmia disease model system may be used to screen for 5 compounds that have the ability to treat arrhythmia. Methods of screening one or more test compounds for treating arrhythmia using the model or system are therefore also provided.
Inventors 4
- Richard, Paul Frank Davis
- Tessa, de Korte
- Benjamin, Blakeley Johnson
- Christine, Lindsay Mummery
Inventors are linked to an Aachen author when surname and first name match exactly one author.
Applicants
- ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC) GBS Leiden
Cited papers 3 in the database
Non-patent literature as cited (12)
- - PATRA C ET AL.: "Biochemistry", 2022, STATPEARLS PUBLISHING
- - KLARENBEEK J ET AL.: "Fourth-generation epac-based FRET sensors for cAMP feature exceptional brightness, photostability and dynamic range: characterization of dedicated sensors for FLIM, for ratiometry and with high affinity", PLOS ONE, vol. 10, 2015
- - SURDO N.C. ET AL.: "FRET biosensor uncovers cAMP nano-domains at beta-adrenergic targets that dictate precise tuning of cardiac contractility", NAT. COMMUN, vol. 8, 2017, pages 15031
- - CAMPOSTRINI, G. ET AL.: "Generation, functional analysis and applications of isogenic three-dimensional self-aggregating cardiac microtissues from human pluripotent stem cells", NATURE PROTOCOLS, vol. 16, 2021, pages 2213 - 2256, XP037424454, DOI: 10.1038/s41596-021-00497-2
- - CHEN YLUN ATLSMYTH GK: "From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline [version 2; peer review: 5 approved", F1000RESEARCH, vol. 5, 2016, pages 1438
- - NOVAK, A.BARAD, L.LORBER, A.GHERGHICEANU, MRAPPAPORT, B: "Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations", J. CELL. MOL. MED., vol. 19, 2015, pages 2006 - 2018
- - FATIMA, AZRA ET AL.: "In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells", CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, vol. 28, no. 4, 2011, pages 579 - 592, XP055565280, DOI: 10.1159/000335753
- - GIACOMELLI, E. ET AL.: "Human-iPSC-Derived Cardiac Stromal Cells Enhance Maturation in 3D Cardiac Microtissues and Reveal Non-cardiomyocyte Contributions to Heart Disease", CELL STEM CELL, vol. 26, 2020, pages 862 - 879
- - KUJALA, K. ET AL.: "Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Reveals Early and Delayed Afterdepolarizations", PLOS ONE, vol. 7, 2012
- - ILANIT ITZHAKI ET AL: "Modeling of Catecholaminergic Polymorphic Ventricular Tachycardia With Patient-Specific Human-Induced Pluripotent Stem Cells", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 60, no. 11, 1 September 2012 (2012-09-01), pages 990 - 1000, XP055200817, ISSN: 0735-1097, DOI: 10.1016/j.jacc.2012.02.066
- - DI PASQUALE E ET AL: "CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia", CELL DEATH & DISEASE, vol. 4, no. 10, 1 October 2013 (2013-10-01), pages e843 - e843, XP055788464, Retrieved from the Internet <URL:http://www.nature.com/articles/cddis2013369> DOI: 10.1038/cddis.2013.369
- - SANDEEP S HOTHI ET AL: "Epac activation, altered calcium homeostasis and ventricular arrhythmogenesis in the murine heart", PFLÜGERS ARCHIV - EUROPEAN JOURNAL OF PHYSIOLOGY, SPRINGER, BERLIN, DE, vol. 457, no. 2, 4 July 2008 (2008-07-04), pages 253 - 270, XP019657968, ISSN: 1432-2013, DOI: 10.1007/S00424-008-0508-3